肝细胞癌代谢标志物的研究进展

孙文博; 刘相良; 李薇

doi:10.3969/j.issn.1001-5256.2018.06.040

肝细胞癌代谢标志物的研究进展

DOI: 10.3969/j.issn.1001-5256.2018.06.040

吉林大学第一医院肿瘤中心

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1430
- HTML全文浏览量: 44
- PDF下载量: 367
- 被引次数: 0
出版历程
- 收稿日期: 2017-11-29
- 出版日期: 2018-06-20

Research advances in metabolic markers for hepatocellular carcinoma

Cancer Center, The First Hospital of Jilin University

摘要

摘要: 肝细胞癌的发病率和病死率高,预后较差,早发现和早诊断是降低肝细胞癌发病率和病死率的主要办法,目前临床常用的血清肿瘤标志物其敏感性和特异性均不能完全满足临床需求。代谢组学主要研究生物体产生的所有代谢产物的变化,例如脂质、胆汁酸、氨基酸等,它们位于系统生物学的下游,能直接反映组织的生化状态。代谢组学通过利用色谱、质谱、磁共振等技术从患者血清、尿液、组织等标本中寻找代谢物的差异,从而探讨其诊断价值并希望发现潜在的肝细胞癌标志物。在肿瘤早期筛查中,代谢组学研究具有标本易得,操作简单,并且可同时处理大量标本等优势。综述了近年来应用代谢组学研究肝细胞癌代谢标志物的相关进展。
- 癌,肝细胞 /
- 肝瘤标记,生物学 /
- 综述
Abstract: Hepatocellular carcinoma (HCC) has high incidence and mortality rates and poor prognosis and greatly threatens human health.Early identification and diagnosis is an important method for reducing the incidence and mortality rates of HCC. The sensitivities and specificities of commonly used serum tumor markers cannot meet the need in clinical practice. Metabolomics focuses on the changes in metabolites produced by organisms, such as lipids, bile acid, and amino acids, which are located at the downstream of systems biology and can directly reflect the biochemical status of tissues. With the help of the techniques including chromatography, mass spectrometry, and magnetic resonance, metabolomics can identify the differences in metabolites in serum, urine, and tissue samples, evaluate their diagnostic values, and help to find potential markers for HCC. In the early screening of tumors, metabolomics has the advantages of easily available specimens, simple operation, and processing a large number of specimens simultaneously. This article reviews the recent research advances in metabolic markers for HCC with the application of metabolomics.
- carcinoma, hepatocellular /
- tumor markers, biological /
- review

HTML全文

参考文献(33)

[1]AKINYEMIJU T, ABERA S, AHMED M, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level:Results from the global burden of disease study 2015[J].JAMA Onclo, 2017, 3 (12) :1683-1691.

[2]CHEN WQ, ZHENG RS, ZHANG SW, et al.Report of cancer incidence and mortality in China, 2013[J].China Cancer, 2016, 26 (1) :1-7. (in Chinese) 陈万青, 郑荣寿, 张思维, 等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2016, 26 (1) :1-7.

[3]LIM C, BHANGUI P, SALLOUM C, et al.Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma[J].J Hepatol, 2017.[Epub ahead of print]

[4]HANAHAN D, WEINBERG RA.Hallmarks of cancer:The next generation[J].Cell, 2011, 144 (5) :646-474.

[5]ABELEV GI.Production of embryonal serum alpha-globulin by hepatomas:Review of experimental and clinical data[J].Cancer Res, 1968, 28 (7) :1344-1350.

[6]KIM JU, SHARIFF MI, CROSSEY MM, et al.Hepatocellular carcinoma:Review of disease and tumor biomarkers[J].World J Hepatol, 2016, 8 (10) :471-484.

[7]SONG P, FENG X, INAGAKI Y, et al.Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China:A multi-center case-controlled study of 1153 subjects[J].Biosci Trends, 2014, 8 (5) :266-273.

[8]SAUZAY C, PETIT A, BOURGEOIS AM, et al.Alpha-foetoprotein (AFP) :A multi-purpose marker in hepatocellular carcinoma[J].Clin Chim Acta, 2016, 463:39-44.

[9]CAVIGLIA GP, ABATE ML, PETRINI E, et al.Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J].Hepatol Res, 2016, 46 (3) :e130-e135

[10]GAO J, SONG P.Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China:Expectation[J].Drug Discov Ther, 2017, 11 (3) :168-169.

[11]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.

[12]WISHART DS.Is cancer a genetic disease or a metabolic disease?[J].Ebiomedicine, 2015, 23, 2 (6) :478-479.

[13]LIU Y, YE N, GONG JP.Research advances in prevention and treatment of primary liver cancer with metabolic agents[J].J Clin Hepatol, 2016, 32 (7) :1413-1417. (in Chinese) 刘彦, 叶楠, 龚建平.代谢类药物治疗和预防原发性肝癌的研究进展[J].临床肝胆病杂志, 2016, 32 (7) :1413-1417.

[14]YANG Y, LI C, NIE X, et al.Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning1H NMR spectroscopy in conjunction with multivariate data analysis[J].J Proteome Res, 2007, 6 (7) :2605-2614.

[15]RESSOM HW, XIAO JF, TULI L, et al.Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis[J].Anal Chim Acta, 2012, 743:90-100.

[16]WANG B, CHEN D, CHEN Y, et al.Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry[J].J Proteome Res, 2012, 11 (2) :1217-1227.

[17]FURUYA H, SHIMIZU Y, KAWAMORI T.Sphingolipids in cancer[J].Cancer Metastasis Rev, 2011, 30 (3-4) :567-576.

[18]FITIAN AI, NELSON DR, LIU C, et al.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS[J].Liver Int, 2014, 34 (9) :1428-1444.

[19]PATTERSON AD, MAURHOFER O, BEYOGLU D, et al.Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling[J].Cancer Res, 2011, 71 (21) :6590-6600.

[20]XIAO JF, VARGHESE RS, ZHOU B, et al.LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort[J].J Proteome Res, 2012, 11 (12) :5914-5923.

[21]LUO P, YIN P, HUA R, et al.A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma[J].Hepatology, 2017.[Epub ahead of print]

[22]di POTO C, FERRARINI A, ZHAO Y, et al.Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery[J].Cancer Epidemiol Biomarkers Prev, 2017, 26 (5) :675-683.

[23]GAO R, CHENG J, FAN C, et al.Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma[J].Sci Rep, 2015, 5:18175.

[24]GONG ZG, ZHAO W, ZHANG J.Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis[J].Oncotarget, 2017, 8 (38) :63890-63900.

[25]ZHANG J, HAO N, LIU W, et al.In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery[J].Br J Cancer, 2017, 117 (11) :1676-1684.

[26]SANABRIA JR, KOMBU RS, ZHANG GF.Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma[J].HPB (Oxford) , 2016, 18 (12) :979-990.

[27]SOGA T, SUGIMOTO M, HONMA M, et al.Serum metabolomics revealsγ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease[J].J Hepatol, 2011, 55 (4) :896-905.

[28]YANG L, YUE S, YANG L, et al.Sphingosine kinase/sphingosine1-phosphate (S1P) /S1P receptor axis is involved in liver fibrosis-associated angiogenesis[J].J Hepatol, 2013, 59 (1) :114-123.

[29]MEYER K, JIA Y, GAO WQ, et al.Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-Co A oxidase null mice[J].Int J Oncol, 2002, 21 (6) :1175-1180.

[30]JAIN M, NILSSON R, SHARMA S, et al.Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation[J].Science, 2012, 336 (6084) :1040-1044.

[31]CHANETON B, HILLMANN P, ZHENG L, et al.Serine is a natural ligand and allosteric activator of pyruvate kinase M2[J].Nature, 2012, 491 (7424) :458-462.

[32]WU FX, WANG Q, ZHANG ZM, et al.Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy[J].Cancer Lett, 2009, 279 (2) :163-170.

[33]MITTAL D, GUBIN MM, SCHREIBER RD, et al.New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape[J].Curr Opin Immunol, 2014, 27:16-25.

施引文献

资源附件(0)

访问统计